Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Peking Union Medical College Hospital20 enrolled

Overview

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Using biochemical markers (such as thyroglobulin), functional markers (such as change of tumor-background ratio on bone scan), etc to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Thyroid Neoplasm Follicular Bone Metastases

Interventions

Sr-89DRUG

1. strontium-89 chloride treatment 2. periodical evaluation and follow-up

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of differentiated thyroid cancer * Positive uptake by bone metastases on bone scan * Planing to have Sr-89 treatment Exclusion Criteria: * Having received treatment for bone metastases within one month of the study (such as radiotherapy, surgery, targeted therapy, chemotherapy, etc., among which denosumab and bisphosphate were allowed as basic treatment) * Having received radioactive iodine therapy within half a year before the study * There are bone related events, such as fracture, spinal cord compression, etc.

Locations (1)

Peking Union Medical College Hospital

Beijing, China

Outcomes

Primary Outcomes

Change of serum thyroglobulin (Tg) level

Change of serum Tg level

Time frame: Through study completion, an average of 1 week in the first months and 1 month thereafter, up to 6 months

Change of serum thyroglobulin antibody (TgAb) level

Change of serum TgAb level

Time frame: Through study completion, an average of 1 week in the first months and 1 month thereafter, up to 6 months

Change of serum calcium level

Time frame: Through study completion, an average of 1 week in the first months and 1 month thereafter, up to 6 months

Change of serum alkaline phosphatase (ALP) level

Change of ALP level

Time frame: Through study completion, an average of 1 week in the first months and 1 month thereafter, up to 6 months

Change of tumor-background ratio on bone scan

Change from baseline tumor-background ratio on bone scan at 3 months and 6 months

Time frame: Baseline, 3 months and 6 months

Change of standardized uptake value (SUV) on positron emission tomography/ computed tomography (PET/CT)

Change from baseline SUV on PET/CT at 3 months and 6 months

Time frame: Baseline, 3 months and 6 months

Secondary Outcomes

Structural change on image

Structural change on image at 3 months and 6 months

Time frame: Baseline, 3 months and 6 months

Central Contacts

Yan-Song Lin

CONTACT

861069155610 linys@pumch.cn

Xian-Feng Cao

CONTACT

861069156874

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.